Pilot and Feasibility Projects at our Institution help establish multidisciplinary collaborations between basic and translational scientists, and integrate well within the overall CF Center. The projects described in this component and associated illustrations reinforce central topics pursued by the P30, including CFTR cellular and structural biology, mechanisms underlying CF tissue pathogenesis, and novel therapeutic interventions for the disease. Pilots are intended to provide initial support for innovative directions and stimulate investigators from other areas to lend their expertise to research concerning CF. The P30 Pilot Program has allowed Center leadership to identify and fund promising early stage research. Functions/goals of this Component are identified by the following Specific Aims:
Specific Aim 1 ? Provide research support that will enable eligible investigators to explore the feasibility of innovative concepts. Projects typically last 1-2 years each, are concordant with the overall objectives of the UAB P30, and are intended to result in further grant support from NIH or other funding agencies.
Specific Aim 2. Provide an administrative framework for oversight and review of Pilot and Feasibility Studies. This includes recommendations regarding continuation (or termination) of Pilots to the P30 Internal Advisory Committee, solicitation and review of Pilot applications, record-keeping with regard to grant and manuscript productivity of Pilot PIs, subsequent career events of awardees, and all aspects of program management. During the current funding cycle, the Pilot and Feasibility Component has been successful as judged by the following criteria: 1) funds were well utilized and awards made to investigators meeting eligibility criteria;2) projects were focused on P30 Center scientific priorities;and 3) Pilot and Feasibility studies were productive (e.g. in terms of publications, subsequent independent R01 or other peer-reviewed support, and/or attraction of new investigator into Center-related research).

Public Health Relevance

From a historical standpoint, Pilot resources have assisted several members of the CF Research Base early in their scientific careers. The Pilot mechanism also helped launch careers of investigators who subsequently accepted faculty positions at outside institutions and continue to pursue CF research. At just four years into its first funding cycle, the UAB P30 Pilot Component has already made important contributions to understanding cystic fibrosis disease mechanism and translational research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK072482-08
Application #
8685243
Study Section
Special Emphasis Panel (ZDK1-GRB-7)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
8
Fiscal Year
2014
Total Cost
$219,750
Indirect Cost
$63,323
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Brand, Jeffrey D; Lazrak, Ahmed; Trombley, John E et al. (2018) Influenza-mediated reduction of lung epithelial ion channel activity leads to dysregulated pulmonary fluid homeostasis. JCI Insight 3:
Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor. Int Forum Allergy Rhinol 8:577-583
Guimbellot, Jennifer S; Acosta, Edward P; Rowe, Steven M (2018) Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol 53:E6-E8
Solomon, George M; Bronsveld, Inez; Hayes, Kathryn et al. (2018) Standardized Measurement of Nasal Membrane Transepithelial Potential Difference (NPD). J Vis Exp :
Reeves, Emer P; O'Dwyer, Ciara A; Dunlea, Danielle M et al. (2018) Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations. Am J Respir Crit Care Med 198:1099-1102
McCormick, Lydia L; Phillips, Scott E; Kaza, Niroop et al. (2018) Maternal Smoking Induces Acquired CFTR Dysfunction in Neonatal Rats. Am J Respir Crit Care Med 198:672-674
Duncan, Gregg A; Kim, Namho; Colon-Cortes, Yanerys et al. (2018) An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene Therapy. Mol Ther Methods Clin Dev 9:296-304
Gelfond, Daniel; Heltshe, Sonya L; Skalland, Michelle et al. (2018) Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening. J Pediatr Gastroenterol Nutr 66:657-663
Birket, Susan E; Davis, Joy M; Fernandez, Courtney M et al. (2018) Development of an airway mucus defect in the cystic fibrosis rat. JCI Insight 3:
Shei, Ren-Jay; Peabody, Jacelyn E; Kaza, Niroop et al. (2018) The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis. Curr Opin Pharmacol 43:152-165

Showing the most recent 10 out of 175 publications